David M Mott insider trades
Open-market stock purchases and sales by David M Mott, Director at Novavax Inc, from SEC Form 4 filings since Nov 21, 2011.
Track record: 16% of 32 scored buys are up 5% or more since purchase, averaging -43%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 20, 2026 | NVAX Novavax Inc | Bought (not open market) | — |
| Jun 18, 2026 | NVAX Novavax Inc | Bought (not open market) | — |
| Jun 18, 2026 | NVAX Novavax Inc | Bought (not open market) | — |
| Jun 16, 2026 | ARDX Ardelyx, Inc | Bought (not open market) | — |
| Jun 16, 2026 | ARDX Ardelyx, Inc | Bought (not open market) | — |
| Jun 16, 2026 | ARDX Ardelyx, Inc | Bought (not open market) | — |
| Feb 20, 2026 | ARDX Ardelyx, Inc | Bought | $1.9M |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | — |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $95.4K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $373K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $119K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | — |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $22.3K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $115K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $124K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $123K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $109K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $108K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $106K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $211K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $163K |
| Jan 6, 2026 | MRSN Mersana Therapeutics, Inc | Sold (not open market) | $159K |
Companies traded
- NVAX Novavax Inc: 5 sales, last Jun 20, 2026
- ARDX Ardelyx, Inc: 19 buys, last Jun 16, 2026
- MRSN Mersana Therapeutics, Inc: 2 buys, last Jan 6, 2026
- ADAP Adaptimmune Therapeutics plc: 9 buys, last Jul 1, 2024
- EPZM Epizyme, Inc: 13 buys, 3 sales, last Aug 12, 2022
- IMRA IMARA Inc: 9 buys, last Jun 2, 2022
- RGLS Regulus Therapeutics Inc: 5 buys, last Dec 24, 2019
- MIRM Mirum Pharmaceuticals, Inc: 1 buy, last Jul 22, 2019
- GNCA Genocea Biosciences, Inc: 1 buy, last Jun 24, 2019
- NITE Nightstar Therapeutics plc: other filings, last Jun 7, 2019
- TRVI Trevi Therapeutics, Inc: 2 buys, last May 9, 2019
- AVEO Aveo Pharmaceuticals Inc: 27 buys, last Apr 8, 2019